Personas / Equipo Humano

Susana Rives Solà

Buscador de publicaciones

Publicaciones

  • Vicente-Garces C, Fernandez-Isern G, Esperanza-Cebollada E, Richarte M, Crespo-Carrasco A, Montesdeoca S, Isola I, Sarrate E, Cuatrecasas E, Rives-Solà S, Dapena JL, Camós-Guijosa M and Vega-García N.

    RNA-sequencing: A reliable tool to unveil transcriptional landscape of paediatric B-other acute lymphoblastic leukaemia.

    BRITISH JOURNAL OF HAEMATOLOGY . 206(5): 1355-1365.

    [doi:10.1111/bjh.20056]

  • Galán-Gómez V, González-Martínez B, Alonso-Saladrigues A, Rives-Solà S, Herrero B, Kwon M, Sánchez-Pina J, Minguillón J, Martínez-Romera I, Mirones Aguilar I, Mestre-Durán C, Casado G, Sánchez-Martín M, Echecopar C, González-Pérez C, León-Triana O, Aguirre-Portolés C, Molinos-Quintana Á, Barba P, Balsalobre P and Pérez-Martínez A.

    Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults.

    Experimental Hematology and Oncology . 14(1): 49-49. Nº de citas: 1

    [doi:10.1186/s40164-025-00638-3]

  • Pearson ADJ, Rossig C, Mackall CL, Shah NN, Baruchel A, Daems S, Anderson J, Biondi A, Bird N, Bodmer N, Brivio E, Buechner J, Calkoen FG, Cooper T, de Rojas T, Fox E, Gardner R, Ghorashian S, Heenen D, Ifversen M, Jacoby E, Juan-Otero M, Knox L, Komanduri K, Larghero J, Locatelli F, Ludwinski D, Majzner RG, McDonough J, Minard-Colin V, Nysom K, Pappo A, Park JR, Qasim W, Quintarelli C, Rives-Solà S, Rouce RH, Scobie N, Seitz C, Tasian SK, Weigel B, Weiner S, Zwaan CM and Vassal G.

    New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis.

    LANCET ONCOLOGY . 26(4): 214-224.

    [doi:10.1016/S1470-2045(24)00736-8]

  • Marina Caballero Bellón, Bobillo-Perez S, Català-Temprano A, Alonso-Saladrigues A, Valls-Lafon A, Rives-Solà S and Jordán-García I.

    Role of procalcitonin, C-reactive protein and ferritin in cytokine release syndrome after CAR T-cell therapy in children and young adults

    Biomarkers . 30(2): 115-122. Nº de citas: 1

    [doi:10.1080/1354750X.2025.2454471]

  • Guerrero-Murillo M, Rill-Hinarejos A, Trincado JL, Bataller A, Ortiz-Maldonado V, Benítez-Ribas D, Español-Rego M, González-Navarro EA, Martínez-Cibrián N, Marchese D, Martín-Martín L, Martín García-Sancho A, Rives-Solà S, Heyn H, Juan M, Urbano-Ispizúa Á, Delgado J, Orfao A, Mereu E, Bueno C and Menendez P.

    Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias

    CELL REPORTS MEDICINE . 5(11): 101803-101803. Nº de citas: 1

    [doi:10.1016/j.xcrm.2024.101803]

  • Theron A, Alonso-Saladrigues A, Dapena JL, López-Duarte M, Diaz de Heredia C, Verdú-Amorós J, Sarrate E, Esperanza-Cebollada E, Cuatrecasas E, Andreu S, Conde N, Sanchez-Sierra N, Isola I, Camós-Guijosa M, Torrebadell-Burriel M, Rives-Solà S and Català-Temprano A.

    Secondary haematological dysplasia after CAR-T-cell therapy for acute lymphoblastic leukaemia in children

    BRITISH JOURNAL OF HAEMATOLOGY . : 186-194.

    [doi:10.1111/bjh.19862]

  • Ruiz-Llobet A, Gassiot S, Sarrate E, Zubicaray J, Rives-Solà S, Suleman W and Berrueco R.

    Thrombin Generation Profile Using ST-Genesia after PEG-asparaginase in Pediatric Patients with Acute Lymphoblastic Leukemia

    THROMBOSIS AND HAEMOSTASIS . 124(10): 973-985.

    [doi:10.1055/a-2316-4547]

  • Pennesi E, Brivio E, Ammerlaan ACJ, Jiang Y, Van der Velden VHJ, Beverloo HB, Sleight B, Locatelli F, Brethon B, Rossig C, Engstler G, Nilsson A, Bruno B, Petit A, Bielorai B, Rizzari C, Rialland F, Rubio-San-Simón A, Sirvent FJB, Diaz-de-Heredia C, Rives-Solà S and Zwaan CM.

    Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial

    HAEMATOLOGICA . 109(10): 3157-3166. Nº de citas: 6

    [doi:10.3324/haematol.2023.284409]

  • Juan-Ribelles A, Bautista F, Cañete A, Rubio-San-Simón A, Alonso-Saladrigues A, Hladun R, Rives-Solà S, Dapena JL, Fernández JM, Lassaletta Á, Cruz-Martínez O, Ramírez-Villar G, Fuster JL, de Heredia CD, García-Ariza M, Quiroga E, Del Mar Andrés M, Verdú-Amorós J, Molinés A, Herrero B, López M, Márquez C, Toboso M, Lendínez F, Sirvent JG, Tallón M, Rodríguez G, Acha T, Moreno L and Fernández-Teijeiro A.

    ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer

    CLINICAL & TRANSLATIONAL ONCOLOGY . 26(9): 2351-2359.

    [doi:10.1007/s12094-024-03445-0]

  • Wu JH, Pennesi E, Bautista F, Garrett M, Fukuhara K, Brivio E, Ammerlaan ACJ, Locatelli F, van der Sluis IM, Rossig C, Chen-Santel C, Bielorai B, Petit A, Starý J, Díaz-de-Heredia C, Rives-Solà S, O'Marcaigh A, Rizzari C, Engstler G, Nysom K, Rubio-San-Simón A, Bruno B, Bertrand Y, Brethon B, Rialland F, Plat G, Dirksen U, Sramkova L, Zwaan CM and Huitema ADR.

    Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059

    CLINICAL PHARMACOKINETICS . 63(7): 981-997. Nº de citas: 2

    [doi:10.1007/s40262-024-01386-z]